Stock comparison
Halozyme Therapeutics
Phibro Animal Health
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.41B
Sector
Healthcare
PAHC
Phibro Animal Health
Market cap
$1.47B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | PAHC | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 41D | HALO |
| Benjamin Graham | 73B | 74B | PAHC |
| Philip Fisher | 55C | 25F | HALO |
| Peter Lynch | 43D | 29F | HALO |
| Joel Greenblatt | 30F | 38D | PAHC |
| Charlie Munger | 70B | 36D | HALO |
| Terry Smith | 74B | 32F | HALO |
Side-by-side metrics
| Metric | HALO | PAHC |
|---|---|---|
| Market cap | $8.41B | $1.47B |
| P/E (TTM) | 24.0x | 15.5x |
| EV/EBIT | 10.2x | 20.0x |
| ROIC (TTM) | 23.65% | 11.17% |
| Gross margin | 81.24% | 32.54% |
| Net margin | 23.13% | 6.35% |
| Revenue CAGR 5y | 33.23% | 11.68% |
| EPS CAGR 5y | -1.98% | -2.92% |
| Debt / Equity | 1.0x | 2.2x |
| Dividend yield | 0.0% | 1.32% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Market cap$8.41Bvs $1.47B+82%
- Net margin23.13%vs 6.35%+73%
- Revenue CAGR 5y33.23%vs 11.68%+65%
- Gross margin81.24%vs 32.54%+60%
PAHC leads on
- Dividend yield1.32%vs 0.0%+100%
- P/E (TTM)15.5xvs 24.0x+36%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.